---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109714"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:59:19.399000+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences reports Q3 2025 results; Phase 1b AD trial over 85% enrolled

## Summary
- Cash $15.4M at Sep 30, 2025, up from $13.3M at Dec 31, 2024; raised ~$21.6M in July 2025.
- Phase 1b PRECISE-AD trial over 85% enrolled; Cohorts 1 and 2 fully enrolled.
- DSMB unanimously recommended proceeding to third dose cohort; interim data Q2 2026, top-line Q4 2026.
- Operating loss $11.8M for Q3 2025 vs $4.4M in Q3 2024, driven by increased R&D on PMN310 trial.

## SEC filing metadata
- accession: 0001104659-25-109714
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/0001104659-25-109714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109714
- JSON: https://secwatch.observer/filing/0001104659-25-109714.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.